89bio (NASDAQ: ETNB) stock is up 48% today on reports about the Phase 2b results on pegozafermin. That the drug is working so far is good and interesting news - the thing we need to take away from this is the absolute importance of the Food and Drug Administration to any valuation of pharmaceutical or treatment development companies. The FDA is the one vital gatekeeper to the market and that's really all that matters.
The economic model here is that the initial research and testing is done near purely on shareholder capital. That then meets a series of tests along the way. Failing any one of the tests means complete failure and the likely loss of all capital invested so far. Continuing to pass all the tests just means progression to the next. It can and often will be a 5 - 10 year process before full FDA authorisation to market the drug or treatment is given. Only then, after that full authorisation, might it be possible to earn back from that capital invested.

That $2 billion is the sort of sum that a start up just isn't going to be able to raise. So, what often happens is that if Phase 2 - ie, the drug actually works - trials are successful then a tie up with one of the pharmaceutical giants is then negotiated. They then aid in carrying the costs of Phase 3.
The real value add to 89bio of good Phase 2b results is that it brings closer that day of a possible tie up with a major.



